Mastitis is characterized as a persistent, inflammatory reaction of the udder tissue in cows. This inflammatory response is commonly due to bacterial infection but may also occur as a result of chemical, mechanical or thermal injury. 

Mastitis is the most common disease in dairy cattle and the most costly to the dairy industry in the United States.  Clinical mastitis causes economic loss due to treatment costs, lost quarters, loss of animals and lost or discarded milk.  Subclinical mastitis may simply creep along quietly reducing milk production and quality until detected with a somatic cell count.  Estimated annual costs to the US dairy industry are between $1.7 and $2.0 billion dollars. 

Common contagious pathogens are Streptococcus agalactiae, Staphylococcus aureus, Mycoplasmas and Corynebacterium bovis.  Common environmental pathogens are Streptococcus uberis and Streptococcus dysgalactaciae, Escherichia coli and Klebsiella pneumoniae. 

Similar to the way healthcare acquired infections in people are transmitted in our hospitals and clinics, mastitis is often transmitted by contact with the milking machine and through contaminated hands and materials. 

At Zurex PharmAgra, we have acquired a new non-antibiotic antimicrobial technology, which has demonstrated significant efficacy and safety in preventing healthcare acquired infections in medical clinics, and applied it to the dairy and veterinary industries.  Through targeted formulation and product development efforts, we have taken this new pharmaceutical technology and developed effective, non-iodine based, broad spectrum antimicrobial products in the teat dip, teat sealant and pre-surgical skin preparation categories. 

ZuraLac™

ZuraSeal™

ZuraPrep™

Publications